Company received $7.5 million in gross proceeds from the initial tranche of Series D Convertible Preferred Stock

公司从D轮可转换优先股的首次交割中获得750万美元的总收益

Agreement provides for up to $17.5 million in additional funding through subsequent tranche closings to support Alzamend's clinical programs and working capital needs

该协议规定，通过后续分批交割提供高达1,750万美元的额外资金，以支持Alzamend的临床项目和营运资金需求。

ATLANTA

亚特兰大

,

，

Aug. 4, 2026

2026年8月4日

/PRNewswire/ --

/美通社/ --

Alzamend Neuro, Inc.

阿尔扎门德神经公司

(Nasdaq:

（纳斯达克：

ALZN

ALZN

) ('

) ('

Alzamend

阿尔扎门德

'), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ('

'），一家专注于开发治疗阿尔茨海默病新型产品的临床阶段生物制药公司（'

Alzheimer's

阿尔茨海默病

'), bipolar disorder ('

'), 双相情感障碍 ('

BD

BD

'), major depressive disorder ('

'), 重度抑郁障碍 ('

MDD

重度抑郁症

') and post-traumatic stress disorder ('

'）和创伤后应激障碍（'

PTSD

创伤后应激障碍

'), announced today that it has entered into a Securities Purchase Agreement (the '

”）今日宣布，已签订一份证券购买协议（“

Agreement

协议

') with Ault Lending, LLC ('

'）与 Ault Lending, LLC（'

Ault Lending

奥尔特借贷

'), pursuant to which Ault Lending has agreed to purchase up to $25,000,000 of the Company's newly designated Series D Convertible Preferred Stock (the '

”），根据该协议，Ault Lending 同意购买公司新指定的 D 系列可转换优先股，金额不超过 25,000,000 美元（“

Preferred Shares

优先股

'), and closed on the initial tranche in the amount of $7.5 million.

），并完成了首笔750万美元的融资交割。

Under the terms of the Agreement, Ault Lending agreed to purchase up to 25,000 Preferred Shares at a purchase price of $1,000 per share, for an aggregate purchase price of $25,000,000, with each Preferred Share having a stated value of $1,050. The Preferred Shares will be purchased in a series of 17 tranche closings.

根据协议条款，Ault Lending 同意以每股 1,000 美元的价格购买最多 25,000 股优先股，总购买价格为 25,000,000 美元，每股优先股的设定价值为 1,050 美元。这些优先股将通过 17 个批次的交割分次购买。

At the initial closing, Ault Lending purchased 7,500 Preferred Shares for a purchase price of $7,500,000. Ault Lending has agreed to purchase an additional 2,500 Preferred Shares for $2,500,000 in a second tranche, expected to close within ten business days after a resale registration statement covering the shares of common stock issuable upon conversion of the Preferred Shares is declared effective by the U.S.

在首次交割时，Ault Lending以7,500,000美元的购买价格购买了7,500股优先股。Ault Lending已同意以2,500,000美元的价格在第二批次中额外购买2,500股优先股，预计该批次交割将在涵盖因转换优先股而可发行的普通股的转售注册声明被美国宣布生效后的十个工作日内完成。

Securities and Exchange Commission (the '.

证券交易委员会（the '.

SEC

美国证券交易委员会

'). The remaining 15,000 Preferred Shares are expected to be purchased in subsequent monthly tranches of $1,000,000 each over approximately 15 months, subject to the satisfaction of customary closing conditions. The Company will pay Ault Lending an origination fee of 2% of the purchase price at each tranche closing..

）。剩余15,000股优先股预计将在约15个月内，以每笔1,000,000美元的月度分期方式陆续购买，但须满足惯例交割条件。公司将在每次分期交割时向Ault Lending支付相当于购买价格2%的发起费。

The Company intends to use the net proceeds from the offering for general working capital and corporate purposes, including to further its clinical trials. In connection with the Agreement, the Company and Ault Lending also entered into a Registration Rights Agreement requiring the Company to register the resale of the shares of common stock issuable upon conversion of the Preferred Shares.  Ault Lending is an indirect, wholly owned subsidiary of Ault Capital Group, Inc ('.

本公司拟将本次发行所得款项净额用于一般营运资金及公司用途，包括进一步推进其临床试验。就该协议而言，本公司与Ault Lending还签订了一份注册权协议，要求本公司登记因优先股转换而可发行的普通股的转售事宜。Ault Lending是Ault Capital Group, Inc.的间接全资子公司。

Ault Capital Group

奥尔特资本集团

').

').

'Ault Lending is proud to support Alzamend as it works toward next-generation treatments for Alzheimer's, BD, MDD and PTSD,' said Milton 'Todd' Ault, III, Executive Chairman of Ault Capital Group and Founder and Chairman Emeritus of Alzamend. 'This mission is personal to me. I have lost family members to Alzheimer's, and I have watched loved ones live with BD, MDD and PTSD.

“Ault Lending 很自豪能够支持 Alzamend，助力其开发针对阿尔茨海默病、双相情感障碍（BD）、重度抑郁症（MDD）和创伤后应激障碍（PTSD）的下一代疗法，”Ault Capital Group 执行董事长兼 Alzamend 创始人及名誉董事长 Milton “Todd” Ault III 表示。“这项使命对我而言具有个人意义。我曾因阿尔茨海默病失去家人，也亲眼目睹挚爱之人深受双相情感障碍、重度抑郁症和创伤后应激障碍的困扰。”

Backing Alzamend's continued clinical progress is exactly the kind of investment Ault Lending was built to make, and I am committed to seeing this research through commercialization.'.

支持Alzamend持续的临床进展，正是Ault Lending创立之初旨在进行的投资类型，我致力于推动这项研究直至实现商业化。

'The funding from Ault Lending will help us further our clinical trials,' said Stephan Jackman, CEO of Alzamend. 'We are working diligently towards completing the next milestone. If we can develop a next-generation lithium product that would not require therapeutic drug monitoring, it would constitute a major improvement over current lithium-based treatments and positively impact the 43.5 million Americans afflicted with Alzheimer's, BD, MDD and PTSD.

“来自Ault Lending的资金将帮助我们进一步推进临床试验，”Alzamend首席执行官Stephan Jackman表示。“我们正 diligently 努力完成下一个里程碑。如果我们能够开发出一种无需进行治疗药物监测的下一代锂产品，这将对目前的基于锂的治疗方法构成重大改进，并对患有阿尔茨海默病、双相情感障碍（BD）、重度抑郁症（MDD）和创伤后应激障碍（PTSD）的4350万美国人产生积极影响。”

Moreover, this funding will enable us to continue our Phase I/IIA safety/tolerability/efficacy clinical trial of our immunotherapeutic vaccine, a potential cure for Alzheimer's.'.

此外，这笔资金将使我们能够继续开展针对我们的免疫治疗疫苗的I/IIA期安全性、耐受性和有效性临床试验，该疫苗有望成为阿尔茨海默病的潜在治愈手段。

Additional information regarding the securities described above and the terms of the Agreement and the Preferred Shares are included in a Current Report on Form 8-K filed with the United States Securities and Exchange Commission on August 3, 2026.

关于上述证券以及协议和优先股条款的更多信息，包含在2026年8月3日向美国证券交易委员会提交的8-K表格当前报告中。

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of shares of Alzamend's common stock in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction..

本新闻稿不构成出售要约或购买要约的招揽，在任何州或其他司法管辖区，若根据该州或其他司法管辖区的证券法，在注册或资格认定之前进行此类要约、招揽或销售属违法行为，则不得在该等州或其他司法管辖区销售Alzamend的普通股。

For more information on Alzamend, stockholders, investors, and any other interested parties may read Alzamend's public filings and press releases available under the Investor Relations section at

如需了解有关 Alzamend 的更多信息，股东、投资者及任何其他感兴趣方均可查阅在投资者关系栏目下提供的 Alzamend 公开备案文件和新闻稿。

https://www.alzamend.com/

https://www.alzamend.com/

or available at

或在以下位置提供

https://www.sec.gov/

https://www.sec.gov/

.

。

About Alzamend Neuro

关于 Alzamend Neuro

Alzamend is a clinical-stage biopharmaceutical company developing novel therapies for Alzheimer's, BD, MDD and PTSD. Our mission is to rapidly develop and market safe and effective treatments. Our current pipeline consists of two novel therapeutic drug candidates, AL001, a patented ionic cocrystal delivering lithium with salicylate and L-proline designed to improve brain delivery and safety compared to conventional lithium, and ALZN002, a patented cell-based therapeutic vaccine designed to restore the immune system's ability to clear Alzheimer's beta-amyloid.

Alzamend 是一家处于临床阶段的生物制药公司，致力于开发针对阿尔茨海默病、双相情感障碍（BD）、重度抑郁障碍（MDD）和创伤后应激障碍（PTSD）的新型疗法。我们的使命是快速开发并上市安全有效的治疗药物。我们目前的研发管线包含两种新型候选治疗药物：AL001 是一种专利离子共晶体，通过水杨酸盐和 L-脯氨酸递送锂，旨在与传统锂制剂相比改善脑部递送效果和安全性；ALZN002 是一种专利细胞基治疗性疫苗，旨在恢复免疫系统清除阿尔茨海默病 β-淀粉样蛋白的能力。

The latter is a next-generation active-immunity approach offering potential advantages in dosing frequency and cost compared to approved passive-immunity antibody therapies. Both candidates are exclusively licensed from the University of South Florida Research Foundation under royalty-bearing worldwide licenses..

后者是一种新一代主动免疫疗法，与已获批的被动免疫抗体疗法相比，在给药频率和成本方面具有潜在优势。这两种候选药物均根据全球范围内的特许权使用费许可协议，独家授权自南佛罗里达大学研究基金会。

Forward-Looking Statements

前瞻性陈述

This press release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as 'believes,' 'plans,' 'anticipates,' 'projects,' 'estimates,' 'expects,' 'intends,' 'strategy,' 'future,' 'opportunity,' 'may,' 'will,' 'should,' 'could,' 'potential,' or similar expressions.

本新闻稿包含经修订的《1933年证券法》第27A条和经修订的《1934年证券交易法》第21E条所定义的“前瞻性陈述”。这些前瞻性陈述通常包括具有预测性质的陈述，其依赖于或提及未来事件或条件，并包含诸如“相信”、“计划”、“预期”、“预测”、“估计”、“期望”、“打算”、“战略”、“未来”、“机会”、“可能”、“将”、“应该”、“能够”、“潜在”或类似表述。

Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties. Forward-looking statements speak only as of the date they are made, and Alzamend undertakes no obligation to update any of them publicly in light of new information or future events.

非历史事实的陈述属于前瞻性陈述。前瞻性陈述基于当前的信念和假设，这些信念和假设受风险和不确定性的影响。前瞻性陈述仅在其发表之日有效，Alzamend 没有义务因新信息或未来事件而公开更新任何此类陈述。

Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. More information, including potential risk factors, that could affect Alzamend's business and financial results are included in Alzamend's filings with the U.S. Securities and Exchange Commission.

由于各种因素，实际结果可能与任何前瞻性陈述中包含的结果存在重大差异。更多可能影响Alzamend业务和财务结果的潜在风险因素等信息，已包含在Alzamend向美国证券交易委员会提交的文件中。

All filings are available at .

所有备案文件均可在 . 获取。

www.sec.gov

www.sec.gov

and on Alzamend's website at

以及在Alzamend的网站上

www.Alzamend.com

www.Alzamend.com

.

。

SOURCE Alzamend Neuro, Inc.

来源：Alzamend Neuro, Inc.

21

二十一

%

%

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示